The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory MM.

NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...

(RTTNews) - AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement to advance SIM0500, an investigational drug ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. The two ...

T-cell engagers have been hot property in recent months, so it’s only right that one the biggest deals to kick off the J.P. Morgan Healthcare conference should see AbbVie expanding its interest ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...

Under the deal, AbbVie will pay Simcere up to $1.06 billion, along with royalties on sales outside China. AbbVie would receive royalties on sales within China. (Reporting by Aaditya Govind Rao in ...

Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop ...